Agomab Key Takeaways From Our 2026 Biotech Conference Call Series

研报英文原文证据摘录

Agomab Key Takeaways From Our 2026 Biotech Conference Call Series

J P M O R G A N North America Equity Research

14 July 2026

Agomab Overweight

AGMB, AGMB US

Key Takeaways From Our 2026 Biotech Conference Price (13 Jul 26):$12.31

Call Series

SMid Biotechnology

Recently, we hosted Agomab as part of our 2026 J.P. Morgan Biotech Conference Anupam Rama AC

Call Series. We wanted to pass on some quick thoughts. (1-212) 622-0900

anupam.rama@jpmorgan.com

• Overall, the company has made strong progress with ontunisertib in Joyce Zhou

Fibrostenosing Crohn’s Disease (FSCD) with recent regulatory progress (1-212) 622-7212

(alignment with FDA on the phase 2b NOV-ERA study). joyce.zhou@jpmorgan.com

J.P. Morgan Securities LLC

• Looking forward, we would note that the company has multiple value-

creating catalysts in 2H26 (for ontunisertib and AGMB-447).

• We see AGMB shares as materially undervalued on the potential of The authors would like to thank Rati

ontunisertib in FSCD alone. Pinge of the J.P. Morgan Global

Research Center for contributions to

• For the NOV-ERA study, relative to the phase 2a experience (STENOVA), this report. Agomab highlighted key study design differences including 1) use of higher

doses of ontunisertib (top-dose being 400mg BID and also assessing 200mg

BID / 100mg BID) in NOV-ERA versus 200mg BID / 100mg QD in the phase

2a STENOVA study, 2) longer follow-up (52-week study for NOV-ERA versus

12-weeks in STENOVA), and 3) the use of a novel primary endpoint in NOV-

ERA (endoscopic passability - discussed in greater detail below).

• On the NOV-ERA primary endpoint of endoscopic passability, the company

noted that 1) it is an objective measure of passability / patency and 2) the

endpoint will allow for distinction from background anti-inflammatory